Vanta Bioscience P/E Ratio
Current P/E Ratio
136.0
High Valuation
Very High - High growth expectations or significantly overvalued
Vanta Bioscience P/E ratio. Vanta Bioscience (VANTABIO) P/E ratio is 136.0 (High), EPS (TTM) ₹0.15, current price ₹ on None — Very High - High growth expectations or significantly overvalued. Examine VANTABIO quarterly performance for recent quarterly revenue, profit and EPS trends.
Current Valuation Metrics
P/E Ratio
136.0
Current Price
₹
EPS (TTM)
₹0.15
Exchange
None
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
54.43
Sector Median
31.69
Sector Rank
#11 of 200
Sector Percentile
5.5%
Earnings Breakdown (TTM)
TTM EPS
₹-3.95
Mar 2022
₹0.11
Dec 2022
₹-4.06
VANTABIO P/E Ratio — Valuation Signal & Historical Context
Vanta Bioscience P/E 136.0 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see VANTABIO share price screener.
- Stock appears overvalued with PE of 136.0, suggesting caution for new investments
- Trading at premium to sector average PE of 54.43
VANTABIO vs Healthcare Peers — P/E Ratio Comparison
Vanta Bioscience P/E 136.0 vs Healthcare average 54.43, median 31.69 — range 2.02–722.21.
Sector Average
54.43
Sector Median
31.69
Lowest P/E
2.02
Highest P/E
722.21
Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.02 | ₹60 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.33 | ₹55 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.86 | ₹6,006 | Low |
| Dipna Pharmachem | DPL | 3.97 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 5.05 | ₹65 | Low |
| Royal Sense | ROYAL | 5.39 | ₹40 | Low |
| Kabra Drugs | KABRADG | 5.47 | ₹41 | Low |
| GKB Ophthalmics | GKB | 5.85 | ₹32 | Low |
| Colinz Laboratories | COLINZ | 6.31 | ₹18 | Low |